MiNK Therapeutics (NASDAQ:INKT) Shares Down 1.6% – Should You Sell?

MiNK Therapeutics, Inc. (NASDAQ:INKT)’s stock price traded down 1.6% during mid-day trading on Tuesday . The stock traded as low as $11.45 and last traded at $11.45. 11,019 shares changed hands during mid-day trading, an increase of 45% from the average daily volume of 7,582 shares. The stock had previously closed at $11.64.

Analysts Set New Price Targets

INKT has been the topic of a number of research reports. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a report on Monday, May 18th. Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Finally, Zacks Research lowered shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Performance

The stock has a market cap of $61.86 million, a P/E ratio of -5.05 and a beta of 0.49. The business has a 50 day simple moving average of $11.17 and a 200-day simple moving average of $11.23.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). On average, sell-side analysts predict that MiNK Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC bought a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.